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Abstract
Human cells respond to DNA damage with an acute and transient burst in production of 
poly(ADP-ribose), a posttranslational modification that expedites damage repair and plays a 
pivotal role in cell fate decisions. Poly(ADP-ribose) polymerases (PARPs) and glycohydrolase 
(PARG) are the key set of enzymes that orchestrate the rise and fall in cellular levels of 
poly(ADP-ribose). In this perspective, we focus on recent structural and mechanistic insights into 
the enzymes involved in poly(ADP-ribose) production and turnover, and we highlight important 
questions that remain to be answered.
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Introduction
Cells respond instantaneously to DNA damage with posttranslational modifications of 
proteins that repair DNA damage, alter gene expression, or control passage through the cell 
cycle. The covalent modification of these proteins induces a dynamic network of protein-
protein interactions and regulates enzymatic activities, broadly changing cellular physiology 
and serving to integrate myriad responses to DNA damage that dictate outcomes for DNA 
repair, cell survival, and responses to chemotherapy. One of the most prodigious 
posttranslational modifications caused by DNA damage is the poly-(ADP-ribosylation) of 
proteins, catalyzed by members of the poly-(ADP-ribose) polymerase (PARP) superfamily 
of NAD+ dependent ADP-ribosyltransferases [1]. Poly-(ADP-ribose) (PAR) is a large, 
negatively-charged and branched polymer that can exceed the mass of the unmodified 
protein. PARylation creates binding sites for PAR-specific binding proteins [2,3] and 
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changes the electrostatic properties of the modified protein, with the notable capacity to 
change DNA binding properties of enzymes, histones, and structural proteins [4]. PARP-1 
itself is the target of most of the poly-(ADP-ribosylation) (PARylation) occurring in 
response to DNA damage. Automodification of PARP-1 increases its association with a 
variety of repair and signaling proteins that are recruited to sites of DNA damage by 
PARP-1 activity [3,5]. In turn, some of these proteins are PARylated by PARP-1.
PARP enzymes responding to damage can consume substantial amounts of cellular NAD+ 
within minutes, changing a cell’s metabolic status while modifying vast numbers of 
proteins, many of which have been only recently identified by proteomic surveys [6,7]. For 
most of these proteins, the effects of PARylation remain to be functionally characterized. 
These studies are complicated by the fact that PAR modifications turn over rapidly due to 
the activity of poly-(ADP-ribose) glycohydrolase (PARG) and mono-(ADP-ribose) 
glycohydrolases (MARGs) [8,9]. Both the synthesis and turnover of poly-(ADP-ribose) 
appear to be important for normal responses to DNA damage. In this short perspective, we 
will review the recent literature on the structures and functions of DNA damage-dependent 
PARPs and PARG, and then speculate about how these activities may be tied 
mechanistically to various disease processes and the resulting opportunities for therapeutic 
intervention.
Structure and mechanism of DNA damage-dependent PARPs
Three members of the PARP superfamily are catalytically activated through interaction with 
DNA damage: PARP-1, PARP-2, and PARP-3. PARP involvement in the cellular response 
to DNA damage has long been appreciated and continues to actively develop [10,11]. A 
general model that has collectively emerged indicates that the DNA-damage dependent 
PARPs act early in the process of damage detection, which promptly results in PARP 
catalytic activation and a burst of PAR production. PARP presence and activity at the 
damage site then can contribute to the efficiency of the repair process and the repair pathway 
choice. A key role of the DNA-damage dependent PARPs and the PAR modification they 
produce is to recruit repair factors to the site of damage. Several motifs and domains have 
been identified in repair proteins that mediate the interaction with PAR and the recruitment 
to sites of PAR synthesis [12,13]. In addition to PAR serving as a recruiting platform, PAR 
modification of repair and chromatin-associated factors in the vicinity of a damage site is 
expected to change the catalytic properties of targeted proteins, and the local structure of 
chromatin [10]. However, detailed insights into PAR-mediated regulation of protein 
function are lacking in general. And although a general model for PARP contribution to the 
DNA damage response has formed, the molecular details of PARP involvement are not 
clearly established, which has limited our understanding of PARP’s contribution to specific 
steps of repair, and the contribution of different PARPs to repair pathway choice. Over 
recent years, structural and biochemical studies have provided key insights into the early 
stages of PARP-1 involvement in DNA repair: the detection of DNA damage, and the 
allosteric coupling of damage detection to acute levels of PAR production. Here we will 
provide an overview of these important insights into PARP-1 mechanism, and we will 
indicate some of the key questions that remain to be answered.
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The DNA-damage dependent PARPs have similar catalytic domain structures, but they 
differ somewhat in the domains that contact DNA damage (Figure 2)[13]. In the catalytic 
domain, they share a conserved structural feature known as the helical domain (HD) [14] 
(also referred to as the PARP regulatory domain – PRD). The HD is only found in the DNA-
damage dependent PARPs, and it plays an important role in regulating PARP catalytic 
activity, as described later. The HD is adjacent to the ADP-ribosyl transferase (ART) fold, 
which is common to all PARP family members. The ART contains the binding site for 
NAD+, which donates ADP-ribose, and a second binding site for an ADP-ribose unit, which 
accepts the next ADP-ribose during the PAR extension reaction that can result in both linear 
and branched polymers [15,16](Figure 2). Detailed structural views of PAR biosynthesis 
(NAD+ binding, initiation on target protein, polymer extension) have not been obtained, thus 
our complete understanding of PAR synthesis is limited. The NAD+ binding sites for the 
DNA-damage dependent PARPs are similar and have the conserved His-Tyr-Glu (HYE) 
amino acids that define catalytically active PARP members capable of forming PAR (as 
opposed to mono-ADP-ribose)[17,18]. The acceptor binding sites vary between PARP-1, 
PARP-2, and PARP-3 and this is likely to influence the type of polymer formed (e.g. 
polymer length, number of branch points). For example, PARP-3 has an Arg residue in the 
acceptor site where PARP-1 and PARP-2 have a Met residue, which is expected to 
contribute to the binding pocket for the adenosine base of an acceptor ADP-ribose 
modification [16]. Presumably this change in sequence perturbs the binding site and 
contributes to the smaller size of polymer produced by PARP-3 [18]. It is not understood 
how the differences in the structure of PAR produced might differentially influence 
downstream signaling to repair pathways, and it will be important to resolve this issue.
Mechanism of PARP-1 activation
Outside of the catalytic domain, the DNA-damage dependent PARPs also have in common a 
Trp-Gly-Arg (WGR) domain that is essential to damage-dependent activation, and is the 
most defining feature of the DNA-damage dependent PARPs. A crystal structure that 
contained the essential domains of PARP-1 in complex with DNA damage provided the first 
views of the WGR domain contacts with DNA (Figure 2). The structure indicated that 
conserved regions of the WGR make sequence-independent contacts with the DNA 
backbone near the 5′ terminus [19]. The importance of these contact residues to catalytic 
activation was confirmed through mutagenesis. Although their are no structures for PARP-2 
and PARP-3 in complex with DNA damage, it is interesting to note that their activation 
levels are sensitive to modifications to the 5′ terminus of the DNA, such as phosphorylation 
[20], suggesting that their WGR domains have specialized interactions with the 5′ terminus. 
PARP-1 in contrast is relatively insensitive to the detailed composition of the break site, 
consistent with the PARP-1 complex structure in which the 5′ terminus is not directly 
contacted [19]. The biochemical results for PARP-2 and PARP-3 suggest that they are most 
potently activated at certain stages of the repair process, for example, when a DNA break 
has been processed to the point of containing a 5′ phosphorylated nick that is competent for 
DNA ligation [20]. Indeed, the efficiency of recovery from a DNA double-strand break 
depends on PARP-3, which is proposed to aid recruitment of the DNA ligation complex that 
completes the NHEJ repair pathway [21]. Hence, there are likely to be important variations 
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in the mechanism of activation for each of the DNA-damage dependent PARPs that 
contribute to their specialization toward distinct repair pathways, and the stage at which they 
act within a given repair pathway. Further structural and biochemical studies will help to 
further define the specifics of the particular PARP involvement in the DNA repair response.
In addition to engaging DNA damage, the WGR domain makes important contacts with the 
HD, and thus physically couples damage detection to the catalytic domain, which does not 
bind DNA [19](Figure 2). These WGR contacts induce destabilizing structural changes in 
the HD that are associated with PARP-1 activation, and they are suggested to involve a 
change in protein dynamics [22]. However, the precise role of HD structural transitions and 
their potential impact on the ART are not clear and require further investigation. 
Understanding these structural changes is likely to be relevant to the mode of PARP 
inhibitor binding, since all clinical PARP inhibitors interact with the ART. WGR–HD 
contacts and their importance to activation are conserved in PARP-2 and PARP-3, as well as 
the destabilizing changes in HD, thus indicating that the allosteric coupling of damage 
detection to catalytic activation will proceed through similar mechanisms for the DNA 
damage-dependent PARPs [20]. In contrast, the DNA damage binding interfaces of 
PARP-1, PARP-2, and PARP-3 are likely to have significant variations based on their 
differences in domain composition. It will be important to understand these differences in 
greater detail, as it will help to clarify the specific roles that each DNA damage-dependent 
PARP performs in repair.
Outside of the WGR domain, there are other regulatory domains that contribute to the 
activation of the DNA-damage dependent PARPs. Most notably, PARP-1 has three N-
terminal zinc-binding domains that contribute to DNA binding and catalytic activation in 
different ways (Figure 2). The crystal structure of PARP-1 essential domains in complex 
with a DNA double-strand break illustrated how the first zinc finger (Zn1 or F1) and the 
third zinc finger (Zn3 or F3) collaborate with the WGR to bind DNA damage (Figure 2). 
Each of these three domains is strictly required for PARP-1 catalytic activation by DNA, 
and the required domain-domain interfaces formed between them when engaging DNA 
represent novel targets for selective inactivation of PARP-1, since the zinc finger domains 
are unique regulatory domains only found in PARP-1 [23,24]. Zn1 plays a central role in 
damage detection by forming contacts with the nucleotide bases that are exposed at the 
DNA double strand break. This mode of interaction is consistent with earlier crystal 
structures of Zn1 and Zn2, each individually bound to a double strand break [25]. In all 
cases, Zn1 and Zn2 do not contact the 5′ and 3′ terminal ends of the break, and thus can 
allow extensions of these ends that are present in different types of DNA damage (e.g. single 
strand breaks). Thus, the Zn1 and Zn2 mode of engagement allows them to engage a variety 
of damage DNA structures. A different mode of DNA interaction was observed in a crystal 
structure of the Zn1-Zn2 fragment of PARP-1 in complex with a double-strand break 
bearing a single nucleotide overhang [26]. Although the Zn2-DNA contacts matched those 
seen in previous structures, the polarity of the Zn1 domain with respect to the DNA 
backbone was reversed. The reversed polarity was surprising given the structural homology 
and sequence identity between Zn1 and Zn2. Moreover, the positioning of the Zn1 in this 
complex sterically prevents the essential WGR domain from binding to the DNA; thus it is 
hard to envision how this binding mode could lead to PARP-1 activation. Lastly, the relative 
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positioning of the Zn1 and Zn2 domains necessitates that they originate from separate 
polypeptides, which is at odds with a number of recent biophysical studies indicating that 
PARP-1 interacts as a monomer with DNA [19,27–30]. Thus, the relevance of the reversed 
binding mode of Zn1 requires further investigation. Indeed, additional structural studies are 
needed to help clarify this discrepancy, and to fully understand how PARP-1 engages 
various types of DNA damage. Furthermore, it will be important to decipher how PARP 
interaction with DNA damage is different from its interaction with undamaged DNA, and 
the functional consequences of these differences [31,32]. Perhaps most notably, the 
structural basis for PARP-1 engaging a single-strand break is a clear gap in our 
understanding of PARP-1 function as a “nick” sensor. PARP-2 and PARP-3 lack the 
extensive regulatory domains seen in PARP-1, but still have extensions N-terminal to the 
WGR that at least play a role in DNA binding and activation [20]; however, there are limited 
structural and mechanistic insights into their N-terminal regions and how they might 
specialize the function of PARP-2 and PARP-3.
Despite the recent advances in understanding DNA damage detection and catalytic 
activation, there are critical deficiencies in our understanding of how PARP modification 
can influence protein structure and activity. Perhaps the most prominent deficiency is our 
understanding of PARP-1 automodification. PARP-1 automodification has two somewhat 
opposing outcomes: recruitment of repair factors to PARP-1 at sites of damage, and release 
of PARP-1 from the site of damage. It is unclear how this transition occurs. There has been 
much recent progress in the identification of PARP automodification sites using mass 
spectrometry [33–37]. However, there is still much to learn in terms of the functional 
consequences of modification at a given site, and whether modification at different residues 
could lead to different outcomes (e.g. PARP-1 mediated recruitment versus PARP-1 
release). Understanding the mechanism of PARP-1 release from DNA damage has relevance 
to the effects of certain clinical PARP inhibitors that prevent the release mechanism to 
varying degrees and “trap” PARP molecules on DNA damage [38,39]. Understanding 
PARG involvement in reversing the PAR modification and regulating PARP function will 
be equally important in understanding both biologically and medically relevant questions.
Turnover of poly-(ADP-ribose) is required for normal responses to DNA 
damage
The enzymatic synthesis of poly-(ADP-ribose) and its degradation are commensurately 
important for normal responses to DNA damage. In mammals, the enzyme poly-(ADP-
ribose) glycohydrolase (PARG) is the main activity that removes poly-(ADP-ribose) from 
proteins by cleaving ribose-ribose bonds [8]. PARG is an abundant enzyme that degrades 
PAR by a combination of endo- and exo- glycohydrolase activity, removing most of the 
PAR polymer but leaving a single ADP-ribose attached to the protein. The remaining ADP-
ribosyl modification can be removed by one of several recently identified mono-(ADP-
ribose) glycohydrolases [33,40].
Genetic disruption of the PARG gene causes embryonic lethality, and decreased PARG 
activity sensitizes cells to a spectrum of DNA damaging agents resembling that caused by 
genetic knockdown of PARP-1 expression or pharmacologic inhibition of PARP activity 
Pascal and Ellenberger Page 5
DNA Repair (Amst). Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
[41]. For example, BRCA2-deficient cells that are markedly sensitive to PARP inhibitors are 
also hypersensitive to PARG inhibition by the nonselective inhibitor, gallotannin [42]. These 
observations suggest that returning transiently PARylated proteins to their unmodified state 
is cytoprotective, and additionally, that the accompanying metabolic conversion of NAD+ 
≫ poly-(ADP-ribose) ≫ ADP-ribose may be important for recovery from damage, as 
discussed below.
Structure and mechanism of PARG
The crystal structure of a bacterial PARG from Thermomonospora curvata [43] revealed an 
evolutionarily conserved fold that is representative of the core structures of mammalian and 
Tetrahymena PARG enzymes [44–47] (Figure 3A). The catalytic domains of these enzymes 
share a mixed α, β architecture resembling a Rossman fold, originally termed a macro 
domain in the transcriptionally repressive histone protein variant, macro-H2A [48]. The 
macro domain fold binds to ADP-ribose monomers and polymers [49], and it is found in 
mono- and poly-(ADP-ribose) glycohydrolases, PAR binding histones, and other enzymes. 
The macro domain of PARG has a prominent substrate binding groove that engages ADP-
ribose, or the tight-binding analog ADP (hydroxymethyl)pyrrolidinediol (ADP-HPD), in the 
crystal structures. The active site of T. curvata PARG is well suited for binding to the 
terminal ADP-ribose of a PAR polymer, consistent with the exo-glycohydrolase activity of 
this enzyme [43]. The C-terminal helix of T. curvata PARG walls off one end of the ADP-
ribose binding site, creating a pocket that can accept the terminal ADP-ribose and would 
interfere with binding to internal sites of the PAR polymer [43]. In contrast, the ADP-ribose 
binding site of mammalian PARGs is open on both ends, enabling a PAR polymer to be 
positioned for endo- cleavage at internal ribose-ribose bonds [44,46]. Endo- cleavage of 
PAR chains underlies a proposed mechanism for PARP-dependent cell death, with the 
generation of oligo-PAR chains that trigger mitochondrial release of the death factor, 
apoptosis inducing factor (AIF) [50,51].
The catalytic schemes proposed for PARG are based on the locations of conserved active 
site residues and the mutational studies supporting their functional importance 
[43,44,46,52]. A lone glutamic acid (E756 in human PARG) is positioned where it can 
function as a general acid and a general base, to facilitate the exchange of the [n+1] poly-
(ADP-ribose) leaving group for a water-derived hydroxyl. Additional contacts with the 2″-
OH, 3″-OH, or 5″O of the ribose” sugar may enhance the reactivity of a oxocarbenium-like 
intermediate for nucleophilic attack by water. Structures of PARG bound to ADP-ribose and 
the dinucleotide (ADP-ribose)2 indicate that the ribose” ring could interact with the side 
chain carboxylates of nearby acidic residues or with a nonbridging oxygen from the α-
phosphorous of the terminal [n] ADP-ribose group, in a substrate-assisted mode of catalysis. 
Substrate-assisted catalysis is well documented in other glycosidases [53,54] and is a 
plausible mechanism for PARG, based on the structural data. Either of two bound waters 
observed in the crystal structure of human PARG could function as the attacking 
nucleophile, and their different positions with respect to the anomeric carbon would support 
either a retaining or inverting mechanism. Additional experimental work on the catalytic 
mechanism of PARG may lead to a better understanding of the nearly 1000-fold 
enhancement of ADP-HPD binding affinity in comparison to ADP-ribose binding [55], and 
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will aid in the rational development of drug-like small molecule inhibitors directed at the 
active site of human PARG.
PAR degradation and DNA repair
During the DNA damage response, PARG activity reverses the automodification of DNA 
bound PARP-1, concurrent with poly-ubiquitinylation of PARP-1 by the E3 ligase CHFR, 
and subsequent proteasomal degradation of PARP-1 [56]. Decreased activity of either 
CHFR or PARG delays repair and causes hypersensitivity to DNA damage [41,57–59], 
indicating that transient PARylation of PARP-1 and the subsequent removal of PARP-1 
from DNA strongly contribute to the repair of DNA strand breaks. How PARP-1 turnover 
contributes to DNA repair is unknown, yet it is relevant to the therapeutic uses and 
outcomes of PARP inhibitors to treat breast and ovarian cancers, or for the development of 
therapeutically useful inhibitors of PARG. The regulation of chromatin-bound PARP-1 at 
sites of DNA damage may enable the remodeling of DNA repair complexes and/or the DNA 
substrate in order to complete the repair. CHFR-dependent removal of PARP-1 may 
promote remodeling of repair intermediates and further curtail PARP-1 enzymatic activity to 
preserve cellular NAD+ levels [56]. The exact role of PARG in this process remains to be 
investigated. The functionally relevant target(s) of PARG activity during DNA strand break 
repair may be proteins other than PARP-1, such as histones or the DNA repair scaffolding 
protein XRCC1, which are modified at sites of PARP-1 activity on chromatin. PARG 
activity also generates biologically active metabolites that may alter the fate of cells 
experiencing high level DNA damage, as discussed below.
PAR turnover and cell death
PAR oligomers and ADP-ribose are the products of PARG endo- and exo- glycohydrolase 
activities, respectively. The cellular levels of these metabolites could increase substantially 
when PARP-1 is hyperactive because PAR is rapidly degraded by PARG [12]. Oligo-PAR 
has been posited as a signaling molecule that triggers a caspase-independent pathway of 
programmed cell death, termed necroptosis or parthanatos [50,51]. Cell death resulting from 
PARP-1 hyperactivation is typically associated with the proteolytic cleavage of apoptosis 
inducing factor (AIF) and its translocation from mitochondria to the nucleus [60]. Under 
some experimental conditions, AIF translocation and cell death are observed in the absence 
of caspase activity, and thus, independent of the intrinsic pathway of apoptosis. Cleavage 
and translocation of AIF are hallmarks of the pathway and the mechanisms that trigger these 
events are under active investigation [61–63]. It has been proposed that oligo-PAR chains 
produced by the combined activities of nuclear PARP-1 and PARG could diffuse out of the 
nucleus and interact with the mitochondrial outer membrane to trigger AIF release [51]. A 
substantial body of compelling evidence for this mechanism has been reported, although 
there are some important details remaining to be clarified. AIF is normally associated with 
the inner mitochondrial membrane, so the reported localization of AIF to the outer surface of 
isolated mitochondria [64] is surprising and will require additional verification. 
Furthermore, purified PARG is predominately an exo-glycohydrolase, producing ADP-
ribose from posttranslationally modified PARP-1 and from purified oligo-PAR chains. It is 
unclear whether oligo-PAR chains would be spared from further digestion by cytoplasmic 
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PARG long enough to function as signaling molecules. A conceivable remedy would be an 
oligo-PAR binding protein functioning as a chaperone during transit of PAR chains from the 
nucleus to mitochondria. In support of the proposed mechanism, overexpression of a 
cytoplasmic isoform of PARG blocks the nuclear translocation of AIF during PARP 
hyperactivation, consistent with an important role for oligo-PAR chains in the necroptosis 
pathway [50]. Determining the exact role of oligo-PAR in the necroptosis cell death 
pathway will have important implications for the pathogenesis and possible treatment of 
disease states related to neuronal excitotoxicity and ischemia-reperfusion injury [63].
The end product of PAR hydrolysis, ADP-ribose, could also signal DNA damage and 
contribute to PARP-dependent cell death. The NAD+ metabolite 2′, 3′-cyclic ADP-ribose 
(cADP-ribose) triggers mobilization of intracellular Ca2+ stores, whereas ADP-ribose and 
cADP-ribose both stimulate the gating activity of a nonselective plasmalemmal Ca2+ 
channel, the transient receptor potential melastatin 2 (TRPM2) channel [65]. TRPM2 
channel activity contributes to the pathogenesis of ischemia-reperfusion (IR) injury, a 
pathological condition associated with high levels of PARP-1 activation [66,67]. A knock-
down of TRPM2 expression decreases cell death and tissue injury caused by IR, as does 
pharmacological inhibition of PARP-1. These observations provide circumstantial evidence 
that TRPM2 channel activity may contribute to PARP-dependent cell death [68]. The 
TRPM2 protein contains a C-terminal gating domain that is homologous to NUDT9, an 
ADP-ribose pyrophosphatase [69,70]. In whole cell and patch clamp experiments, the 
application of ADP-ribose to the intracellular surface of the membrane causes an immediate 
stimulation of TRPM2 channel activity, which is further enhanced by low levels of Ca2+. 
These results argue for a direct role of ADP-ribose as a positive effector of TRPM2 
mediated calcium fluxes.
TRPM2 channel activity and increasing intracellular Ca2+ could promote AIF-dependent 
cell death in several ways. Elevated intracellular Ca2+ activates the cysteine protease 
calpain-μ, which cleaves AIF’s N-terminal membrane anchor to release AIF into the 
mitochondrial intermembrane space [71]. Egress of cleaved AIF from the mitochondrion 
requires permeabilization of the outer mitochondrial membrane, and a number of 
mechanisms for this have been proposed [60]. In particular, dysregulation of intracellular 
Ca2+ levels causes mitochondrial depolarization by promoting the mitochondrial 
permeability transition, which may facilitate the release of AIF into the cytoplasm.
Therapeutic interventions directed at poly (ADP-ribose) metabolism
A growing number of PARP inhibitors in clinical trials show promise for the treatment of 
cancer, although the exact mechanism(s) of their tumor-selective killing effects remain 
enigmatic [72]. Inhibitors targeting the active site of PARP-1 suffer from dose limiting 
toxicity, which may result from inadequate binding specificity and off target effects on other 
PARP family members. As an alternative strategy, inhibitors blocking the DNA-dependent, 
allosteric activation of PARP-1 enzymatic activity may be more selective for PARP-1 and 
therefore a safer therapeutic strategy [24]. Additionally, inhibitors of the poly (ADP-ribose) 
glycohydrolase PARG may also prove useful for killing repair-deficient tumors, and 
possibly with fewer side effects, since PARG is monogenic and without paralogs [42,73]. 
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Pharmacological agents targeting poly (ADP-ribose) metabolism may have other therapeutic 
applications as well, such as the treatment of stroke and other neurological injuries, or acute 
myocardial infarction [61,74].
Responses to DNA damage are highly complex and present a multitude of potential targets 
for therapeutic interventions aimed at selectively killing cells with dysregulated growth or 
sparing tissues with limited regenerative capacity from harmful insults [75]. The robust 
synthesis and turnover of poly (ADP-ribose) during the DNA damage response, catalyzed by 
PARP-1 and PARG, represents a broad paradigm for interrogating many facets of DNA 
repair, damage signaling, and programmed cell death through the use of small molecule 
ligands. Our growing understanding of the structures and catalytic mechanisms of PARP-1 
and PARG will guide the rational development of pharmacological agents that be invaluable 
for examining the dynamic interplay of pathways that determine cell fate in normal and 
diseased tissues.
Abbreviations
PAR poly(ADP-ribose)
PARP PAR polymerase
PARG PAR glycohydrolase
MARG mono-(ADP-ribose) glycohydrolase
PARylation poly(ADP-ribosylation)
References
1. Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays. 2004; 26:882–
893.10.1002/bies.20085 [PubMed: 15273990] 
2. Žaja R, Mikoč A, Barkauskaite E, Ahel I. Molecular Insights into Poly(ADP-ribose) Recognition 
and Processing. Biomolecules. 2013; 3:1–17.10.3390/biom3010001 [PubMed: 24970154] 
3. Krietsch J, Rouleau M, Pic É, Ethier C, Dawson TM, Dawson VL, et al. Reprogramming cellular 
events by poly(ADP-ribose)-binding proteins. Mol Aspects Med. 2013; 34:1066–1087.10.1016/
j.mam.2012.12.005 [PubMed: 23268355] 
4. Leung AKL. Poly(ADP-ribose): an organizer of cellular architecture. J Cell Biol. 2014; 205:613–
619.10.1083/jcb.201402114 [PubMed: 24914234] 
5. Malanga M, Althaus FR. Noncovalent protein interaction with poly(ADP-ribose). Methods Mol 
Biol. 2011; 780:67–82.10.1007/978-1-61779-270-0_5 [PubMed: 21870255] 
6. Gagné JP, Pic É, Isabelle M, Krietsch J, Ethier C, Paquet E, et al. Quantitative proteomics profiling 
of the poly(ADP-ribose)-related response to genotoxic stress. 2012; 40:7788–7805.10.1093/nar/
gks486
7. Jungmichel S, Rosenthal F, Altmeyer M, Lukas J, Hottiger MO, Nielsen ML. Proteome-wide 
identification of poly(ADP-Ribosyl)ation targets in different genotoxic stress responses. Mol Cell. 
2013; 52:272–285.10.1016/j.molcel.2013.08.026 [PubMed: 24055347] 
8. Feng X, Koh DW. Roles of poly(ADP-ribose) glycohydrolase in DNA damage and apoptosis. Int 
Rev Cell Mol Biol. 2013; 304:227–281.10.1016/B978-0-12-407696-9.00005-1 [PubMed: 
23809438] 
9. Min W, Wang ZQ. Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential. Front 
Biosci. 2009; 14:1619–1626.10.2741/3329
Pascal and Ellenberger Page 9
DNA Repair (Amst). Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
10. De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA 
damage repair: Current state of the art. Biochem Pharmacol. 2012; 84:137–146.10.1016/j.bcp.
2012.03.018 [PubMed: 22469522] 
11. Caldecott KW. Protein ADP-ribosylation and the cellular response to DNA strand breaks. DNA 
Repair (Amst). 2014; 19:108–113.10.1016/j.dnarep.2014.03.021 [PubMed: 24755000] 
12. Barkauskaite E, Jankevicius G, Ladurner AG, Ahel I, Timinszky G. The recognition and removal 
of cellular poly(ADP-ribose) signals. Febs J. 2013; 280:3491–3507.10.1111/febs.12358 [PubMed: 
23711178] 
13. Karlberg T, Langelier MF, Pascal JM, Schüler H. Structural biology of the writers, readers, and 
erasers in mono- and poly(ADP-ribose) mediated signaling. Mol Aspects Med. 2013; 34:1088–
1108.10.1016/j.mam.2013.02.002 [PubMed: 23458732] 
14. Ruf A, Mennissier de Murcia J, de Murcia G, Schulz GE. Structure of the catalytic fragment of 
poly(AD-ribose) polymerase from chicken. Proceedings of the National Academy of Sciences. 
1996; 93:7481–7485.10.1073/pnas.93.15.7481
15. Ruf A, de Murcia G, Schulz GE. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as 
derived from crystal structures and homology modeling. Biochemistry. 1998; 37:3893–
3900.10.1021/bi972383s [PubMed: 9521710] 
16. Steffen JD, Brody JR, Armen RS, Pascal JM. Structural Implications for Selective Targeting of 
PARPs. Front Oncol. 2013; 3:301.1–14.10.3389/fonc.2013.00301 [PubMed: 24392349] 
17. Hottiger MO, Hassa PO, Lüscher B, Schüler H, Koch-Nolte F. Toward a unified nomenclature for 
mammalian ADP-ribosyltransferases. Trends Biochem Sci. 2010; 35:208–219.10.1016/j.tibs.
2009.12.003 [PubMed: 20106667] 
18. Vyas S, Matic I, Uchima L, Rood J, Žaja R, Hay RT, et al. Family-wide analysis of poly(ADP-
ribose) polymerase activity. Nat Commun. 2014; 5:4426:1–13.10.1038/ncomms5426 [PubMed: 
25043379] 
19. Langelier MF, Planck JL, Roy S, Pascal JM. Structural Basis for DNA Damage-Dependent 
Poly(ADP-ribosyl)ation by Human PARP-1. Science. 2012; 336:728–732.10.1126/science.
1216338 [PubMed: 22582261] 
20. Langelier MF, Riccio AA, Pascal JM. PARP-2 and PARP-3 are selectively activated by 5′ 
phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1. 
Nucleic Acids Res. 2014; 42:7762–7775.10.1093/nar/gku474 [PubMed: 24928857] 
21. Rulten SL, Fisher AEO, Robert I, Zuma MC, Rouleau M, Ju L, et al. PARP-3 and APLF function 
together to accelerate nonhomologous end-joining. Mol Cell. 2011; 41:33–45.10.1016/j.molcel.
2010.12.006 [PubMed: 21211721] 
22. Langelier MF, Pascal JM. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-
ribose) synthesis. Curr Opin Struct Biol. 2013; 23:134–143.10.1016/j.sbi.2013.01.003 [PubMed: 
23333033] 
23. Steffen JD, Pascal JM. New players to the field of ADP-ribosylation make the final cut. Embo J. 
2013; 32:1205–1207.10.1038/emboj.2013.83 [PubMed: 23572078] 
24. Steffen JD, Tholey RM, Langelier MF, Planck JL, Schiewer MJ, Lal S, et al. Targeting PARP-1 
allosteric regulation offers therapeutic potential against cancer. Cancer Res. 2013; 74:31–
37.10.1158/0008-5472.CAN-13-1701 [PubMed: 24189460] 
25. Langelier MF, Planck JL, Roy S, Pascal JM. Crystal structures of poly(ADP-ribose) polymerase-1 
(PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent 
PARP-1 activity. J Biol Chem. 2011; 286:10690–10701.10.1074/jbc.M110.202507 [PubMed: 
21233213] 
26. Ali AAE, Timinszky G, Arribas-Bosacoma R, Kozlowski M, Hassa PO, Hassler M, et al. The zinc-
finger domains of PARP1 cooperate to recognize DNA strand breaks. Nat Struct Mol Biol. 2012; 
19:685–692.10.1038/nsmb.2335 [PubMed: 22683995] 
27. Lilyestrom W, van der Woerd MJ, Clark N, Luger K. Structural and biophysical studies of human 
PARP-1 in complex with damaged DNA. J Mol Biol. 2010; 395:983–994.10.1016/j.jmb.
2009.11.062 [PubMed: 19962992] 
28. Eustermann S, Videler H, Yang JC, Cole PT, Gruszka D, Veprintsev D, et al. The DNA-binding 
domain of human PARP-1 interacts with DNA single-strand breaks as a monomer through its 
Pascal and Ellenberger Page 10
DNA Repair (Amst). Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
second zinc finger. J Mol Biol. 2011; 407:149–170.10.1016/j.jmb.2011.01.034 [PubMed: 
21262234] 
29. Mansoorabadi SO, Wu M, Tao Z, Gao P, Pingali SV, Guo L, et al. Conformational activation of 
poly(ADP-ribose) polymerase-1 upon DNA binding revealed by small-angle X-ray scattering. 
Biochemistry. 2014; 53:1779–1788.10.1021/bi401439n [PubMed: 24588584] 
30. Spagnolo L, Barbeau J, Curtin NJ, Morris EP, Pearl LH. Visualization of a DNA-PK/PARP1 
complex. Nucleic Acids Res. 2012; 40:4168–4177.10.1093/nar/gkr1231 [PubMed: 22223246] 
31. Zilio N, Williamson CT, Eustermann S, Shah R, West SC, Neuhaus D, et al. DNA-dependent 
SUMO modification of PARP-1. DNA Repair (Amst). 2013; 12:761–773.10.1016/j.dnarep.
2013.07.001 [PubMed: 23871147] 
32. Clark NJ, Kramer M, Muthurajan UM, Luger K. Alternative modes of binding of poly(ADP-
ribose) polymerase 1 to free DNA and nucleosomes. J Biol Chem. 2012; 287:32430–
32439.10.1074/jbc.M112.397067 [PubMed: 22854955] 
33. Sharifi R, Morra R, Appel CD, Tallis M. Deficiency of terminal ADP-ribose protein 
glycohydrolase TARG1/C6orf130 in neurodegenerative disease. Embo J. 2013; 32:1225–
1237.10.1038/emboj.2013.51 [PubMed: 23481255] 
34. Chapman JD, Gagné JP, Poirier GG, Goodlett DR. Mapping PARP-1 auto-ADP-ribosylation sites 
by liquid chromatography-tandem mass spectrometry. J Proteome Res. 2013; 12:1868–
1880.10.1021/pr301219h [PubMed: 23438649] 
35. Tao Z, Gao P, Liu HW. Identification of the ADP-ribosylation sites in the PARP-1 
automodification domain: analysis and implications. J Am Chem Soc. 2009; 131:14258–
14260.10.1021/ja906135d [PubMed: 19764761] 
36. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue resource 
of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer 
xenograft models. Cancer Res. 2013; 73:4885–4897.10.1158/0008-5472.CAN-12-4081 [PubMed: 
23737486] 
37. Daniels CM, Ong SE, Leung AKL. Phosphoproteomic approach to characterize protein mono- and 
poly(ADP-ribosyl)ation sites from cells. J Proteome Res. 2014; 13:3510–3522.10.1021/pr401032q 
[PubMed: 24920161] 
38. Ström CE, Johansson F, Uhlén M, Szigyarto CAK, Erixon K, Helleday T. Poly (ADP-ribose) 
polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-
strand intermediate. Nucleic Acids Res. 2011; 39:3166–3175.10.1093/nar/gkq1241 [PubMed: 
21183466] 
39. Murai J, Huang SYN, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and 
PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72:5588–
5599.10.1158/0008-5472.CAN-12-2753 [PubMed: 23118055] 
40. Rosenthal F, Feijs KLH, Frugier E, Bonalli M, Forst AH, Imhof R, et al. Macrodomain-containing 
proteins are new mono-ADP-ribosylhydrolases. Nat Struct Mol Biol. 2013; 20:502–507.10.1038/
nsmb.2521 [PubMed: 23474714] 
41. Gao H, Coyle DL, Meyer-Ficca ML, Meyer RG, Jacobson EL, Wang ZQ, et al. Altered poly(ADP-
ribose) metabolism impairs cellular responses to genotoxic stress in a hypomorphic mutant of 
poly(ADP-ribose) glycohydrolase. Exp Cell Res. 2007; 313:984–996.10.1016/j.yexcr.2006.12.025 
[PubMed: 17276427] 
42. Fathers C, Drayton RM, Solovieva S, Bryant HE. Inhibition of poly(ADP-ribose) glycohydrolase 
(PARG) specifically kills BRCA2-deficient tumor cells. Cell Cycle. 2012; 11:990–997.10.4161/cc.
11.5.19482 [PubMed: 22333589] 
43. Slade D, Dunstan MS, Barkauskaite E, Weston R, Lafite P, Dixon N, et al. The structure and 
catalytic mechanism of a poly(ADP-ribose) glycohydrolase. Nature. 2011; 477:616–620.10.1038/
nature10404 [PubMed: 21892188] 
44. Kim IK, Kiefer JR, Ho CMW, Stegeman RA, Classen S, Tainer JA, et al. Structure of mammalian 
poly(ADP-ribose) glycohydrolase reveals a flexible tyrosine clasp as a substrate-binding element. 
Nat Struct Mol Biol. 2012; 19:653–656.10.1038/nsmb.2305 [PubMed: 22609859] 
Pascal and Ellenberger Page 11
DNA Repair (Amst). Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
45. Dunstan MS, Barkauskaite E, Lafite P, Knezevic CE, Brassington A, Ahel M, et al. Structure and 
mechanism of a canonical poly(ADP-ribose) glycohydrolase. Nat Commun. 2012; 3:878.10.1038/
ncomms1889 [PubMed: 22673905] 
46. Tucker JA, Bennett N, Brassington C, Durant ST, Hassall G, Holdgate G, et al. Structures of the 
Human Poly (ADP-Ribose) Glycohydrolase Catalytic Domain Confirm Catalytic Mechanism and 
Explain Inhibition by ADP-HPD Derivatives. PLoS ONE. 2012; 7:e50889.10.1371/journal.pone.
0050889 [PubMed: 23251397] 
47. Wang Z, Gagné JP, Poirier GG, Xu W. PLOS ONE: Crystallographic and Biochemical Analysis of 
the Mouse Poly(ADP-Ribose) Glycohydrolase. PLoS ONE. 201410.1371/journal.pone.
0086010.g005
48. Pehrson JR, Fried VA. MacroH2A, a core histone containing a large nonhistone region. Science. 
1992; 257:1398–1400. [PubMed: 1529340] 
49. Karras GI, Kustatscher G, Buhecha HR, Allen MD, Pugieux C, Sait F, et al. The macro domain is 
an ADP-ribose binding module. Embo J. 2005; 24:1911–1920.10.1038/sj.emboj.7600664 
[PubMed: 15902274] 
50. Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW, Sasaki M, et al. Poly(ADP-ribose) (PAR) 
polymer is a death signal. Proc Natl Acad Sci USA. 2006; 103:18308–18313.10.1073/pnas.
0606526103 [PubMed: 17116882] 
51. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, et al. Apoptosis-inducing factor 
mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA. 2006; 
103:18314–18319.10.1073/pnas.0606528103 [PubMed: 17116881] 
52. Barkauskaite E, Brassington A, Tan ES, Warwicker J, Dunstan MS, Banos B, et al. Visualization 
of poly(ADP-ribose) bound to PARG reveals inherent balance between exo- and endo-
glycohydrolase activities. Nat Commun. 2013; 410.1038/ncomms3164
53. Rempel BP, Withers SG. Covalent inhibitors of glycosidases and their applications in biochemistry 
and biology. Glycobiology. 2008; 18:570–586.10.1093/glycob/cwn041 [PubMed: 18499865] 
54. Gloster TM, Davies GJ. Glycosidase inhibition: assessing mimicry of the transition state. Org 
Biomol Chem. 2010; 8:305–320.10.1039/B915870G [PubMed: 20066263] 
55. Slama JT, Aboul-Ela N, Goli DM, Cheesman BV, Simmons AM, Jacobson MK. Specific 
inhibition of poly(ADP-ribose) glycohydrolase by adenosine diphosphate 
(hydroxymethyl)pyrrolidinediol. Journal of Medicinal Chemistry. 1995; 38:389–393. [PubMed: 
7830282] 
56. Liu C, Wu J, Paudyal SC, You Z, Yu X. CHFR is important for the first wave of ubiquitination at 
DNA damage sites. 2013; 41:1698–1710.10.1093/nar/gks1278
57. Amé JC, Fouquerel E, Gauthier LR, Biard D, Boussin FD, Dantzer F, et al. Radiation-induced 
mitotic catastrophe in PARG-deficient cells. Journal of Cell Science. 2009; 122:1990–
2002.10.1242/jcs.039115 [PubMed: 19454480] 
58. Koh DW, Lawler AM, Poitras MF, Sasaki M, Wattler S, Nehls MC, et al. Failure to degrade 
poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc 
Natl Acad Sci USA. 2004; 101:17699–17704.10.1073/pnas.0406182101 [PubMed: 15591342] 
59. Fujihara H, Ogino H, Maeda D, Shirai H, Nozaki T, Kamada N, et al. Poly(ADP-ribose) 
Glycohydrolase Deficiency Sensitizes Mouse ES Cells to DNA Damaging Agents. Curr Cancer 
Drug Targets. 2009; 9:953–962.10.2174/156800909790192419 [PubMed: 20025604] 
60. Sevrioukova IF. Apoptosis-inducing factor: structure, function, and redox regulation. Antioxid 
Redox Signal. 2011; 14:2545–2579.10.1089/ars.2010.3445 [PubMed: 20868295] 
61. Fatokun AA, Dawson VL, Dawson TM. Parthanatos: mitochondrial-linked mechanisms and 
therapeutic opportunities. Br J Pharmacol. 2014; 171:2000–2016.10.1111/bph.12416 [PubMed: 
24684389] 
62. Delavallee L, Cabon L, Galan-Malo P, Lorenzo HK, Susin SA. AIF-mediated caspase-independent 
necroptosis: a new chance for targeted therapeutics. IUBMB Life. 2011; 63:221–232.10.1002/iub.
432 [PubMed: 21438113] 
63. Aredia F, Scovassi AI. Poly(ADP-ribose): A signaling molecule in different paradigms of cell 
death. Biochem Pharmacol. 2014; 92:157–163.10.1016/j.bcp.2014.06.021 [PubMed: 24976506] 
Pascal and Ellenberger Page 12
DNA Repair (Amst). Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
64. Wang Y, Kim NS, Haince JF, Kang HC, David KK, Andrabi SA, et al. Poly(ADP-ribose) (PAR) 
binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death 
(parthanatos). Sci Signal. 2011; 4:ra20–14.10.1126/scisignal.2000902 [PubMed: 21467298] 
65. Guse AH. Calcium mobilizing second messengers derived from NAD. Biochim Biophys Acta. 
201410.1016/j.bbapap.2014.12.015
66. Yang KT, Chang WL, Yang PC, Chien CL, Lai MS, Su MJ, et al. Activation of the transient 
receptor potential M2 channel and poly(ADP-ribose) polymerase is involved in oxidative stress-
induced cardiomyocyte death. Cell Death Differ. 2006; 13:1815–1826.10.1038/sj.cdd.4401813 
[PubMed: 16294211] 
67. Yamamoto S, Takahashi N, Mori Y. Chemical physiology of oxidative stress-activated TRPM2 
and TRPC5 channels. Prog Biophys Mol Biol. 2010; 103:18–27.10.1016/j.pbiomolbio.
2010.05.005 [PubMed: 20553742] 
68. Blenn C, Wyrsch P, Bader J, Bollhalder M, Althaus FR. Poly(ADP-ribose)glycohydrolase is an 
upstream regulator of Ca2+ fluxes in oxidative cell death. 2011; 68:1455–1466.10.1007/
s00018-010-0533-1
69. Sumoza-Toledo A, Penner R. TRPM2: a multifunctional ion channel for calcium signalling. J 
Physiol (Lond). 2011; 589:1515–1525.10.1113/jphysiol.2010.201855 [PubMed: 21135052] 
70. Shen BW, Perraud AL, Scharenberg A, Stoddard BL. The crystal structure and mutational analysis 
of human NUDT9. J Mol Biol. 2003; 332:385–398. [PubMed: 12948489] 
71. Norberg E, Gogvadze V, Ott M, Horn M, Uhlén P, Orrenius S, et al. An increase in intracellular 
Ca2+ is required for the activation of mitochondrial calpain to release AIF during cell death. Cell 
Death Differ. 2008; 15:1857–1864.10.1038/cdd.2008.123 [PubMed: 18806756] 
72. Lord CJ, Tutt ANJ, Ashworth A. Synthetic Lethality and Cancer Therapy: Lessons Learned from 
the Development of PARP Inhibitors. Annu Rev Med. 2015; 66:455–470.10.1146/annurev-
med-050913-022545 [PubMed: 25341009] 
73. Blenn C, Wyrsch P, Althaus FR. The Ups and Downs of Tannins as Inhibitors of Poly(ADP-
Ribose)glycohydrolase. Molecules. 2011; 16:1854–1877.10.3390/molecules16021854 [PubMed: 
21343889] 
74. Curtin NJ, Szabó C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. 
Mol Aspects Med. 2013; 34:1217–1256.10.1016/j.mam.2013.01.006 [PubMed: 23370117] 
75. Pearl LH, Schierz AC, Ward SE, Al-Lazikani B, Pearl FMG. Therapeutic opportunities within the 
DNA damage response. Nat Rev Cancer. 2015; 15:166–180.10.1038/nrc3891 [PubMed: 
25709118] 
Pascal and Ellenberger Page 13
DNA Repair (Amst). Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. The rise and fall of poly(ADP-ribose)
The ADP-ribose posttranslational modification regulates many fundamental aspects of 
human biology. During the DNA damage response, there is an acute and transient burst of 
poly(ADP-ribose) production and turnover that facilitates repair and contributes to important 
cell fate signaling events.
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Figure 2. DNA damage response PARPs
Three human PARP enzymes are catalytically activated through binding to DNA damage: 
PARP-1, PARP-2, and PARP-3. The WGR domain and the HD region of the catalytic 
domain are defining and unique features of the DNA damage-dependent PARPs. PARP-1 
consists of multiple domains that assume an active conformation upon binding to DNA 
damage. Zinc finger domains 1 and 3 (Zn1 and Zn3) interact with a DNA break and pack 
against the WGR domain, which serves as an intermediary between the C-terminal catalytic 
and N-terminal DNA binding domains, and allosterically couples damage detection to 
catalytic activation.
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Figure 3. PARG structure and catalytic mechanism
A. The catalytic domain of human poly (ADP-ribose) glycohydrolase PARG (residues 
448-976) consists of a macro domain (green; residues 611-812) flanked by N-terminal and 
C-terminal helical bundles (orange). The high affinity inhibitor adenosine diphosphate 
hydroxymethyl(pyrrolidinediol) (ADP-HPD; blue) is bound in the active site cleft, flanked 
by a β-hairpin structure termed the tyrosine clasp (red). Tyrosine 795 from the tyrosine clasp 
interacts with the α-phosphate of ADP-HPD and ADP-ribose (see panel B). B. The active 
site of PARG features a catalytic glutamate (Glu 756) and polar residues that engage the 
ribose and pyrrolidine hydroxyl groups of ADP-HPD and two bound water molecules (red 
spheres). The bound waters are positioned on either face of the carbon corresponding to the 
anomeric position of a poly (ADP-ribose) substrate (yellow circle), where they could 
function as the attacking nucleophile in a retaining (Wat A) or inverting (Wat B) mechanism 
of hydrolysis. C. Proposed catalytic mechanisms for PARG [43,46] assign Glu 756 as the 
catalytic acid that protonates the ADP-ribose leaving group, and as the catalytic base that 
activates a water nucleophile for attack of the anomeric carbon of ribose”. An interaction 
between the α-phosphorous and the 04″ of ribose (N of the pyrrolidine ring shown here) 
may stabilize the carbenium intermediate to assist catalysis.
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